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Primary Prevention of Cardiovascular
Mortality and Events With Statin Treatments
A Network Meta-Analysis Involving More Than 65,000 Patients
Edward J. Mills, MSC, PHD, LLM,* Beth Rachlis, MSC,§ Ping Wu, MBBS, MSC,
Philip J. Devereaux, MD, PHD,*† Paul Arora, MSC,¶ Dan Perri, BSCPHARM, MD, FRCP(C)†‡
Hamilton and Toronto, Ontario, and Vancouver, British Columbia, Canada; and London, United Kingdom
Objectives This study aimed to evaluate the effectiveness of 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitors (statins) in
primary prevention of cardiovascular events.
Background The role of statins is well established for secondary prevention of cardiovascular disease (CVD) clinical events
and mortality. Little is known of their role in primary cardiovascular event prevention.
Methods We conducted comprehensive searches of 10 electronic databases from inception to May 2008. We contacted
study investigators and maintained a comprehensive bibliography of statin studies. We included randomized
trials of at least 12-month duration in predominantly primary prevention populations. Two reviewers indepen-
dently extracted data in duplicate. We performed random-effects meta-analysis and meta-regression, calculated
optimal information size, and conducted a mixed-treatment comparison analysis.
Results We included 20 randomized clinical trials. We pooled 19 trials (n  63,899) for all-cause mortality and found a
relative risk (RR) of 0.93 (95% confidence interval [CI]: 0.87 to 0.99, p  0.03 [I2  5%, 95% CI: 0% to 51%]).
Eighteen trials (n  59,469) assessed cardiovascular deaths (RR: 0.89, 95% CI: 0.81 to 0.98, p  0.01 [I2 
0%, 95% CI: 0% to 41%]). Seventeen trials (n  53,371) found an RR of 0.85 (95% CI: 0.77 to 0.95, p  0.004
[I2  61%, 95% CI: 38% to 77%]) for major cardiovascular events, and 17 trials (n  52,976) assessed myocar-
dial infarctions (RR: 0.77, 95% CI: 0.63 to 0.95, p  0.01 [I2  59%, 95% CI: 24% to 74%]). Incidence of cancer
was not elevated in 10 trials (n  45,469) (RR: 1.02, 95% CI: 0.94 to 1.11, p  0.59 [I2  0%, 95% CI: 0% to
46%]), nor was rhabdomyolysis (RR: 0.97, 95% CI: 0.25 to 3.83, p  0.96 [I2  0%, 95% CI: 0% to 40%]). Our
analysis included a sufficient sample to reliably answer our primary outcome of CVD mortality.
Conclusions Statins have a clear role in primary prevention of CVD mortality and major events. (J Am Coll Cardiol 2008;52:
1769–81) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.08.039i
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tlevated cholesterol levels are a proven risk factor for
ardiovascular diseases (CVDs) (1). Observational studies
ave provided consistent relationships between increased
holesterol and mortality, CVD, and decreased quality of
ife (2). A large number of well-conducted randomized trials
ave established that 3-hydroxy-3-methylglutaryl coenzyme
reductase inhibitor (statin drugs) lowers cholesterol levels
n a variety of different populations and risk groups, includ-
rom the Departments of *Clinical Epidemiology and Biostatistics and †Medicine
nd the ‡Centre for Evaluation of Medicines, McMaster University, Hamilton,
ntario, Canada; §Department of Healthcare and Epidemiology, University of
ritish Columbia, Vancouver, British Columbia, Canada; Department of Epidemi-
logy, London School of Hygiene and Tropical Medicine, London, United Kingdom;
nd the ¶Centre for Global Health, University of Toronto, Toronto, Ontario,
anada. Over the last 5 years, Dr. Mills has consulted for Pfizer Ltd., the Bill and
elinda Gates Foundation, the World Health Organization, and UNHCR.a
Manuscript received July 1, 2008; revised manuscript received August 20, 2008,
ccepted August 25, 2008.ng both primary prevention and secondary prevention of
VD (3). These compelling results have influenced clinical
ractice and policy regarding provision of statins as a general
ront-line therapy for hypercholesterolemia, resulting in the
reatest insurance reimbursement costs of any prescription
rug over the past 10 years (4,5).
Several important systematic reviews currently exist
howing the clinical effectiveness of statins across CVD
utcomes in secondary prevention populations (3,6). Three
ecent systematic reviews have examined specifically primary
revention populations and come to discordant conclusions
bout the role of statins in clinical events and mortality
7–9).
Although some clinicians may use statins for primary
revention of CVD, it is important to determine whether,
rom the totality of evidence to date, statins have a role in
his population. Using a systematic review of the literature
nd meta-analytic techniques, we aimed to quantify the
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Primary Prevention of CVD November 25, 2008:1769–81effects of statin therapy on impor-
tant clinical end points and any
associated mortality benefit. We
additionally examined whether
specific statins exerted important
therapeutic differences across the
class of drugs.
Methods
Eligibility criteria. We in-
cluded any randomized clinical
trial of atorvastatin, fluvastatin,
lovastatin, pitavastatin, pravasta-
tin, rosuvastatin, or simvastatin.
We did not include cerivastatin
as it has been withdrawn from
the market because of serious
adverse events. We included only
randomized clinical trials of at
east a 12-month duration. We defined studies as primary
revention if the majority (50%) of the population had no
istory of coronary heart disease (CHD) (9). Studies had to
ompare a statin with placebo, standard therapy, or no
reatment and report on any of the following clinically
mportant cardiovascular outcomes: all-cause mortality,
VD mortality, fatal myocardial infarction (MI), nonfatal
I, and major coronary events. We excluded studies only
eporting on surrogate outcomes (e.g., low-density lipopro-
ein [LDL] and high-density lipoprotein [HDL] levels) and
ollow-up studies in which randomization had been sub-
erted (10). We additionally excluded studies enrolling
igh-risk diabetic patients (in which the predicted 10-year
isk of a major coronary event or stroke exceeded approxi-
ately 20%) (11).
earch strategy. In consultation with a medical librarian,
e established a search strategy (available from authors on
equest). We searched independently, in duplicate, the
ollowing 10 databases (from inception to May 2008):
EDLINE, EMBASE, Cochrane CENTRAL, AMED,
INAHL, TOXNET, Development and Reproductive
oxicology, Hazardous Substances Databank, PsychINFO
nd Web of Science, databases that included the full text of
ournals (OVID, ScienceDirect, and Ingenta, including
rticles in full text from approximately 1,700 journals since
993). In addition, we searched the bibliographies of
ublished systematic reviews (3,6,7,12–17) and health tech-
ology assessments (8,9,18). Finally, we searched our own
omprehensive rolling database of statin trials, updated
onthly. We also contacted the investigators of all trials for
tudy clarifications, where required, and the investigators of
he only individual patient data meta-analysis of statins,
hich included 14 trials (3,17). Searches were not limited by
anguage, gender, or age.
tudy selection. Two investigators (E.M., P.W.) working
Abbreviations
and Acronyms
CHD  coronary heart
disease
CI  confidence interval
CrI  credibility interval
CVD  cardiovascular
disease
HDL  high-density
lipoprotein
IQR  interquartile range
LDL  low-density
lipoprotein
MI  myocardial infarction
OIS  optimal information
size
RR  relative riskndependently, in duplicate, scanned all abstracts and ob- lained the full-text reports of records that indicated or
uggested that the study was a randomized clinical trial
valuating statin therapy on the outcomes of interest. After
btaining full reports of the candidate trials (either in full
eer-reviewed publication or press article), the same review-
rs independently assessed eligibility from full-text articles.
ata collection. The same 2 reviewers conducted data
xtraction independently using a standardized pre-piloted
orm. The reviewers collected information about the statin
nd type of interventions tested; the population studied
age, gender, underlying conditions); the treatment effect on
pecified outcomes; proportion change in LDL, HDL,
riglycerides, and total cholesterol; and the length of follow-
p. Study evaluation included general methodological qual-
ty features, including blinding, use of intent-to-treat anal-
sis, and allocation concealment (19). We extracted data on
he incidence of the following clinical outcomes: all-cause
ortality, CVD mortality, MI mortality, stroke mortality,
on-CVD mortality, major CVD, MI, strokes, revascular-
zation, angina, rehospitalization, cancers, and rhabdomy-
lysis. We entered the data into an electronic database such
hat duplicate entries existed for each study; when the 2
ntries did not match, we resolved differences through
iscussion and consensus.
ata analysis. To assess inter-rater reliability on inclusion
f articles, we calculated the phi statistic, which provides a
easure of interobserver agreement independent of chance
20). We calculated the relative risk (RR) and appropriate
5% confidence intervals (CIs) of outcomes according to the
umber of events reported in the original studies’ or substudies’
ntent-to-treat analyses. When studies did not report intent-
o-treat analysis, we analyzed outcomes as all patients random-
zed (21). In the case of an individual patient data meta-
nalysis of 14 trials, we included outcomes as reported by the
eta-analysis, in correspondence with the study’s investigators.
n the event of zero outcome events in 1 arm of a trial, we
pplied the Haldane method and added 0.5 to each arm (22).
e pooled studies as an analysis of all statins combined using
he DerSimonian-Laird random effects method (23), which
ecognizes and anchors studies as a sample of all potential
tudies and incorporates an additional between-study compo-
ent to the estimate of variability (24). To evaluate the relative
ffectiveness of each study drug, we used the Lu-Ades method
or combining direct and indirect evidence in mixed-treatment
omparisons (25). We estimated the posterior densities for all
nknown parameters using the Markov Chain Monte Carlo
ethod for each model. Each chain used 100,000 iterations
ith a burn-in number of 500, thin interval of 5, and updates
arying between 80 and 110. We used the same seed number
SEED  314,159) for all chains. The choice of burn-in was
ade according to the Gelman-Rubin approach (26). We
ssessed convergence based on trace plots and time series plots.
he accuracy of the posterior estimates was found by calculat-
ng the Monte Carlo error for each parameter. As a rule of
humb, the Monte Carlo error for each parameter of interest is
ess than about 5% of the sample standard deviation. All results
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November 25, 2008:1769–81 Primary Prevention of CVDor the mixed-treatment analysis are reported as posterior
eans with corresponding 95% credibility intervals (CrIs).
redibility intervals are the Bayesian equivalent of classical
Is. We calculated the I2 statistic for each all-statin analysis as
measure of the proportion of the overall variation that is
ttributable to between-study heterogeneity (27), and calcu-
ated the appropriate I2 CIs (28). Given the expected small
umber of included trials, we conducted a univariate random-
ffects logistic regression assessing the impact of study quality,
s determined by allocation concealment reporting (29), and
ercent LDL change between groups. We additionally con-
ucted a separate subgroup analysis of low-risk population
rials for the outcome of CVD death. We defined a population
s low risk when patients did not have hemodynamically
ignificant atherosclerotic disease (including symptomatic ath-
rosclerotic disease) or had fewer than 3 CVD risk factors.
inally, we determined the optimal information size (OIS) for
ur meta-analysis on the primary outcome of cardiovascular
ortality to determine the conservative number of patients
equired to provide an authoritative answer of therapeutic
fficacy (30). We imputed the experimental and control event
ates from our meta-analysis and applied a 95% power at the
% significance level. Forest plots are shown for each all-statins
nalysis of our primary analyses and a combined forest plot is
hown for secondary outcomes, showing individual and pooled
stimates with 95% CIs, and the overall DerSimmonian-Laird
ooled estimate. Forest plots display the mixed-treatment
omparisons with 95% CrIs. Analyses were conducted using
tatsDirect (version 2.5.2, StatsDirect Ltd., Manchester,
nited Kingdom), Stata (version 9, Stata Corporation, College
tation, Texas), and WinBUGS version 1.4 (Medical Re-
earch Council Biostatistics Unit, Cambridge, United
ingdom).
esults
ur literature search identified 1,003 relevant abstracts of
ull-text articles. Of these, 164 full-text articles reported on
4 clinical trials addressing clinical outcomes, 22 that
ddressed the outcomes of interest for this study. A recently
ompleted trial of rosuvastatin remains unpublished, al-
hough it was stopped early for unreported efficacy results
31,32). A further 2 trials were excluded for enrolling
iabetic patients with high-risk comorbidities (33,34).
here was near-perfect agreement between reviewers on
nclusion of the 20 studies enrolling a total of 65,261
atients (phi  0.85) (Fig. 1) (21,35–53).
Table 1 shows the study characteristics. The median
ample size of the included studies is 1,582 (interquartile
ange [IQR]: 538 to 6,200). We included 4 studies assessing
torvastatin (total n  15,907) (39,40,42,53), 3 studies
ssessing fluvastatin (total n  3,463) (37,41,50), 11 studies
ssessing pravastatin (total n  38,367) (21,38,43–
9,51,52), and 2 studies assessing lovastatin (n  7,524)
35,36). No published rosuvastatin or simvastatin trials met
ur inclusion criteria. All applicable studies reported blind- nng participants and assessors. Intent-to-treat analysis is
eported as the primary analysis in all but 1 study (21).
llocation concealment was reported inconsistently (10 of
0 trials).
We pooled 19 trials (n  63,899) (21,35–40,42–53)
ssessing statins for all-cause mortality and found an RR of
.93 (95% CI: 0.87 to 0.99, p 0.03 [I2 5%, 95% CI: 0%
o 51%, heterogeneity p  0.39]) (Fig. 2). When we
xamined studies reporting allocation concealment in the
eta-regression, we found that studies reporting this meth-
dological issue identified a weaker therapeutic effect (OR:
.14, 95% CI: 1.01 to 1.28, p 0.02). The LDL proportion
hange did not predict all-cause mortality ( coefficient:
0.07, 95% CI: 0.22 to 0.06, p  0.29).
We pooled 17 trials (n  59,469) (35–40,42–49,51–53)
ssessing CVD deaths and found an RR of 0.89 (95% CI:
.81 to 0.98, p  0.02 [I2  0%, 95% CI: 0% to 41%,
eterogeneity p  0.50]) (Fig. 3). In this analysis, studies
eporting allocation concealment exerted a weaker therapeu-
ic effect (OR: 1.23, 95% CI: 1.02 to 1.49, p  0.03). The
DL change did not predict all-cause mortality ( coeffi-
ient: 0.11, 95% CI: 0.11 to 0.34, p  0.33). When we
ooled only trials involving low-risk populations (7 trials, n
23,284) (35,36,43,45,46,49,51), we found a pooled RR of
.66 (95% CI: 0.50 to 0.87, p  0.001).
We also examined MI-attributable mortality and in-
luded 9 trials (n  17,783) (21,35,42–45,48,51,53). The
R was 0.46 (95% CI: 0.26 to 0.79, p  0.005 [I2  0%,
5% CI: 0% to 43%, p  0.90]) (Fig. 4). Given the small
Figure 1 Flow Diagram of Included Studies
CVD  cardiovascular disease; RCT  randomized controlled trial.umber of studies, we did not conduct meta-regression.
Characteristics of Included Studies
Table 1 Characteristics of Included Studies
Study Target Population
Patient
Statin/
Control, n
Mean
Follow-Up,
yrs
Patient
Treated as
Primary
Prevention,
%
Patient Characteristics
Dose,
mg/day
Baseline Level, Statin/Control (mg/dl)
Age,
yrs
Female,
%
Diabetes,
%
Active
Smoker,
%
Mean SBP,
mm Hg
Total
Cholesterol LDL-C HDL-C Triglycerides
Atorvastatin
ASCOT-LLA Substudy of patients with
hypertension, average
or lower cholesterol,
and at least 3 other
CV factors
5,168/5,137 3.3 81.5 63.1 81.1 24.3 33.2 164.2 10 211.6/211.6 134.2/134.2 50.1/50.1 146.9/146.1
ASPEN Patients with type 2
diabetes without high
LDL-C levels
1,211/1,199 4 (median) 78.6 61.0 33.6 100.0 12.0 133 10 194/194 113/114 47/47 147/145
CARDS Patients with diabetes
without high LDL-C
levels
1,428/1,410 3.9 100.0 61.5 32.0 100.0 22.0 144 10 206.5/206.9 3.04/3.02 1.39/1.42 150.4/147.7
Mohler
2003
Patients with peripheral
arterial disease
240/114 1.0 100.0 68.0 22.9 17.5 40.4 10 210/210 130/130
Fluvastatin
ALERT Patients who had
received renal or
combined renal and
pancreas transplants,
had stable graft
function
1,050/1,052 5.1 93.0 50.0 22.9 18.8 40.4 144 40–80 247/251 159.9/159.9 50.7/54.6 194.7/194.7
BCAPS Patients with plaque in
the right carotid artery
but with no symptoms
of carotid artery
disease
395/398 3.0 95.7 62.0 54.5 3.2 30.8 138 40 236.3 159.9 53.8 103.5
HYRIM Men receiving drug
treatment for
hypertension
283/285 4.0 100.0 57.0 0.0 0.0 17.6 140.5 40 225.5/229.7 147.42/150.4 49.5/49.5 154.9/159.3
Lovastatin
ACAPS Asymptomatic patients
with early carotid
atherosclerosis
460/459 2.8 100.0 62.0 48.4 2.3 12.0 130.6 20–40 235.2/235.2 156.5/154.6 51.7/52.7 318.6
AFCAPS/
TexCAPS
Patients with average or
below-average
cholesterol levels
3,304/3,301 5.2 100.0 58.0 15.0 3.8 3.8 138 20–40 221 150 36 (men),
40 (women)
158
Pravastatin
ALLHAT-LLT Substudy of patients with
hypertension,
moderate
hypercholesterolemia,
1 additional CHD
factor
5,170/5,185 4.8 85.8 66.4 51.0 34.4 23.3 145 20–40 223.7/223.7 145.6/145.5 47.6/47.4 150.6/152.8
Continued on next page
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Table 1 Continued
Study Target Population
Patient
Statin/
Control, n
Mean
Follow-Up,
yrs
Patient
Treated as
Primary
Prevention,
%
Patient Characteristics
Dose,
mg/day
Baseline Level, Statin/Control (mg/dl)
Age,
yrs
Female,
%
Diabetes,
%
Active
Smoker,
%
Mean SBP,
mm Hg
Total
Cholesterol LDL-C HDL-C Triglycerides
CAIUS Patients with moderately
elevated LDL levels,
free of symptoms of
CAD, and at least 1
carotid artery lesion
151/154 3.0 100.0 55.0 46.9 NA 24.0 133.6 40 259.5/262.5 181.7/183.7 1.35/1.38 138/137
FAST Asymptomatic patients
with primary
hypercholesterolemia
83/81 2.0 85.8 66.1 32.0 23.0 59.0 130.8 10 251.5/255.2 160.7/171.6 56.7/56.5 168.7/135.8
KAPS Men ages 42, 48, 54, 60
yrs; high LDL-C
224/223 3.0 92.4 57.0 0.0 2.5 26.2 136.7 40 259/259 189/189 46/46 150.4/150.4
KLIS Substudy with men with
high serum Tc levels
2,219/1,634 5.1 100.0 58.0 0.0 23.6 39.8 NA 258/244 50/49
MEGA Patients with a
body weight of
40 kg or more,
hypocholesterolemia
3,866/3,966 5.3 100.0 58.0 68.0 20.6 20.9 132.0 10–20 242.1/242.1 158/158 58.1/58.1 127.4/127.4
PHYLLIS Patients with untreated
hypertension,
hypercholesterolemia,
asymptomatic carotid
atherosclerosis, no
previous CV disease
254/254 2.6 100 58 59.7 NA 16.1 159.0 40 262.2/261.8 183.3/182.5 52.7/53.8 141.6/140.7
PMSG Patients with
hypercholesterolemia
530/532 1.5 59.6 55 23.3 0 28.7 20–40 262.9/265.3 184.8/181.7 44.6/44.9 156.6/164.6
PREVEND IT Substudy in patients with
persistent
microalbuminuria
433/431 3.8 98.2 51 35.1 2.55 39.9 130.5 40 223.9/223.9 159.9/156 39/39 123.9/115.0
PROSPER Older patients with at
least 1 CV risk factor
2,891/2,913 3.2 100 75 58.0 12.2 33.4 156.6 40 220* 150* 37* 154*
WOSCOPS Men with
hypercholesterolemia
3,302/3,293 4.9 83.8 55.3 0.0 1.0 44.0 135.0 40 274* 193* 42* 158*
*Change between groups.
CAD  coronary artery disease; CHD  congenital heart disease; CV  cardiovascular; HDL-C  high-density lipoprotein cholesterol; LDL  low-density lipoprotein; LDL-C  low-density lipoprotein cholesterol; SBP  systolic blood pressure; Tc  total cholesterol; trial
abbreviations as in Figure 2.
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Primary Prevention of CVD November 25, 2008:1769–81We pooled 11 trials (n  31,035) (35,37,38,42–48,53)
ssessing stroke mortality and found a pooled RR of 1.05
95% CI: 0.79 to 1.39, p  0.72 [I2  0%, 95% CI: 0% to
3%, heterogeneity p  0.53]) (Fig. 4). This is consistent
ith a recent meta-analysis we conducted examining stroke
ortality in primary prevention of stroke, addressed in the
iscussion (54).
We evaluated statin effects on noncardiovascular deaths in
8 trials (n  63,333) (21,35–40,42–49,51–53) and found a
onsignificant RR of 0.98 (95% CI: 0.90 to 1.07, p  0.62
I2 0%, 95% CI: 0% to 46%, heterogeneity p 0.59]) (Fig.
). This finding makes inherent sense because statins predom-
nantly reduce CVD morbidity and mortality.
We also evaluated statin effects on major cardiovascular
vents in 17 trials (n  53,371) (35–45,47,48,50–53) and
ound an RR of 0.85 (95% CI: 0.77 to 0.95, p 0.004 [I2
1%, 95% CI: 38% to 77%, heterogeneity p  0.001]) (Fig.
). Heterogeneity is explained in the meta-regression by
eporting of allocation concealment. Studies reporting ap-
Figure 2 Random-Effects Meta-Analysis: All-Cause Mortality
Forest plot shows pooled study relative risk with bars representing 95% confidence
Air Force/Texas Coronary Atherosclerosis Prevention Study; ALERT  Assessment
ment to Prevent Heart Attack Trial–Lipid Lowering Trial; ASCOT-LLA  Anglo-Scandi
vention of Coronary Heart Disease Endpoints in Non–Insulin-Dependent Diabetes M
CAIUS  Carotid Atherosclerosis Italian Ultrasound Study; CARDS  Collaborative
tension High Risk Management trial; KAPS  Kuopio Atherosclerosis Prevention S
lesterol in the Primary Prevention Group of Adult Japanese; PHYLLIS  Plaque Hyp
for Cardiac Risk Patients; PREVEND IT  Prevention of Renal and Vascular Endsta
Vascular Disease; WOSCOPS  West of Scotland Coronary Prevention Study.ropriate allocation concealment had a marginally weaker 6herapeutic effect (OR: 1.09, 95% CI: 1.01 to 1.20,
 0.03).
We evaluated statin effects on MIs in 17 trials (n 
2,976) (21,35–37,39,40,42–49,51–53) and found an RR of
.77 (95% CI: 0.63 to 0.95, p  0.01 [I2  59%, 95% CI:
4% to 74%, heterogeneity p  0.001]) (Fig. 4). We
xplained heterogeneity according to whether allocation
oncealment was reported. Again, studies reporting appro-
riate allocation concealment exerted a weaker therapeutic
ffect (OR: 1.16, 95% CI: 1.01 to 1.35, p  0.04).
We evaluated statin effects on all-stroke incidence in 18
rials (n  57,430) (21,35,37–49,51–53) and found an RR
f 0.88 (95% CI: 0.78 to 1.00, p 0.05 [I2 15%, 95% CI:
% to 53%, heterogeneity p  0.27]) (Fig. 4). Studies
eporting allocation concealment yielded a weaker therapeu-
ic effect (OR: 1.26, 95% CI: 1.05 to 1.49, p  0.01).
We evaluated statin effects on revascularization in 13
rials (n  37,439) (35–37,40,42–48,51,53) and found a
ooled RR of 0.84 (95% CI: 0.66 to 1.08, p  0.18 [I2 
vals (CIs). ACAPS  Asymptomatic Carotid Artery Progression Study; AFCAPS 
col in Renal Transplant; ALLHAT-LLT  Antihypertensive and Lipid-Lowering Treat-
Cardiac Outcomes Study Trial Lipid-Lowering Arm; ASPEN  Atorvastatin for Pre-
s; BCAPS  Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study;
statin Diabetes Study; FAST  Fukuoka Atherosclerosis Trial; HYRIM  Hyper-
LIS  Kyushu Lipid Intervention Study; MEGA  Management of Elevated Cho-
ion Lipid-Lowering Italian Study; PMSG  Pravastatin Multinational Study Group
ease Intervention Trial; PROSPER  Pravastatin in Elderly Individuals at Risk ofinter
of Les
navian
ellitu
Atorva
tudy; K
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ge Dis6%, 95% CI: 36% to 81%, heterogeneity p  0.001])
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November 25, 2008:1769–81 Primary Prevention of CVDFig. 4). Allocation concealment did not explain heteroge-
eity (OR: 1.06, 95% CI: 0.93 to 1.21, p  0.38).
We evaluated statin effects on angina in 11 trials (n 
8,598) (35,36,39,40,42,43,45,47,48,51,53) and found a
onsignificant effect (RR: 1.01, 95% CI: 0.67 to 1.52, p 
Figure 3 Random-Effects Meta-Analysis: Cardiovascular Diseas
Forest plot shows pooled study relative risk with bars representing 95% CIs. Abbre
Figure 4 Pooled Estimates: Secondary Outcomes
Plotted pooled estimates of secondary outcomes. Pooled relative risk with bars re
95% confidence intervals (CIs). CVD  cardiovascular disease; MI  myocardial in.95 [I2  79%, 95% CI: 60% to 89%, heterogeneity p 
.0001]) (Fig. 4). Given the small number of studies (n 
) contributing event data, we did not conduct meta-
egression. In addition, we examined 5 studies reporting on
ehospitalization (35,40,45,47,49) and found an RR of 0.94
rtality
s as in Figure 2.
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Primary Prevention of CVD November 25, 2008:1769–8195% CI: 0.76 to 1.15, p  0.52 [I2  0%, 95% CI: 0% to
%, heterogeneity p  0.89]) (Fig. 4).
We also examined the effect of statins on cancer incidence
n 10 trials (n  45,469) (21,35,36,38,42,45–47,51,53) and
ound a nonsignificant RR of 1.02 (95% CI: 0.94 to 1.11,
 0.59 [I2  0% to 46%, heterogeneity p  0.70]) (Fig. 5).
Finally, we examined the incidence of rhabdomyolysis
eported in 9 trials (n 39,383) (35–37,39,40,42,47,50,51),
ut only 4 contributed events. The pooled RR is 0.97 (95%
I: 0.25 to 3.83, p  0.96 [I2  0%, 95% CI: 0% to 40%,
eterogeneity p  0.85]) (Fig. 5).
ixed-treatment comparison. Our mixed-treatment
omparison analysis permits inferences into the relative
ffectiveness of the intervention. Figure 6 shows the geo-
etric distribution of the mixed-treatment comparisons.
able 2 presents estimates of the absolute risk of mortality
or each treatment, along with the estimated probability that
Figure 5 Pooled Estimates: Adverse Events
Plotted pooled estimates of adverse events cancer and rhabdomyolysis. Pooled st
Figure 6 Geometric Distribution of Analysis
Network of evidence formed by the 4 statin treatments and the placebo treat-
ment. Each treatment strategy is a node in the network. The links between
nodes are trials or pairs of trial arms. The numbers along the link lines indi-
cate the number of trials or pairs of trial arms for that link in the network.Cach treatment is best. Figure 7 shows the relative contri-
ution of each statin to all other statins for all-cause
ortality and Figure 8 for CVD mortality. Tables 3 and 4
rovide the point estimates and 95% CrI values for treat-
ent comparisons.
ptimal information size (OIS). When we calculated the
IS for CVD mortality, informed by the event rates in the
eta-analysis (Fig. 3), with a conservative power of 95%
nd a 1% alpha, we required a sample size of 30,794,
ndicating that our analysis includes almost double (1.93)
he required number of participants to reliably answer the
ole of statins in CVD mortality primary prevention.
iscussion
e examined the impact of statin therapy on major events
nd found an important role in preventing all-cause mor-
ality and most important clinical events in a primary
revention population. We further found that statins seem
o be safe within this population, a finding in line with
econdary prevention populations (3). Our analysis repre-
ents the most comprehensive meta-analysis of statin ther-
py for primary prevention to date.
lative risk with bars representing 95% confidence intervals (CIs).
ixed Treatment Comparison Probabilities of Eachreatment at Reducing All-Cause Mortality andVD Mo t li y
Table 2
Mixed Treatment Comparison Probabilities of Each
Treatment at Reducing All-Cause Mortality and
CVD Mortality
All-Cause Mortality
Probability Best
CVD Mortality
Probability Best
Placebo 0.00 0.00
Atorvastatin 0.48 0.07
Fluvastatin 0.08 0.30
Pravastatin 0.14 0.02
Lovastatin 0.30 0.60udy reVD  cardiovascular disease.
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November 25, 2008:1769–81 Primary Prevention of CVDThe benefits of statins for major clinical events is of clear
mportance to both the developing and the developed world,
o both individual clinicians as well as policy makers, and
cross sex, age, and CHD history (55,56). What seems to be
f prime concern now is the appropriate use of statin
herapy from a public health perspective (18,57). As policy
akers aim to develop guidelines on widespread use of
tatins, the relative effectiveness of statins, along with other
onsiderations of adverse effect profile, tolerability, and
osts, need to be weighed to determine which statins health
inistries should be supplying and who should provide
hem (58,59).
Our analysis utilized a mixed-treatment analysis, a strat-
gy by which the relative effectiveness of each intervention
an be evaluated while maintaining the benefits of random-
zation (60). Although indirect evidence provides compel-
ing evidence of effectiveness, only direct evidence from
arge head-to-head trials can determine which statins pro-
ide the greatest protection from clinically important events.
he PROVE-IT (Pravastatin or Atorvastatin Evaluation
nd Infection Therapy) and ASAP (Effects of Atorvastatin
ersus Simvastatin on Atherosclerosis Progression) trials
re the only statin head-to-head effectiveness trials available
61,62); they compared aggressive therapy with atorvastatin
o standard therapy with pravastatin or simvastatin, and as a
Figure 7 Mixed-Treatment Comparison Analysis of All-Cause M
Forest plot of mixed-treatment comparisons examining relative effectiveness of ea
for all-cause mortality. Estimates are pooled odds ratios with bars representing 95esult, do not inform whether individual drugs had greater ifficacy. A previous meta-analysis examined the extent to
hich statins differ and found no differences among placebo
rials, but did find differences between atorvastatin and
imvastatin and atorvastatin and pravastatin when combined
ith usual care controls (6). That meta-analysis included
nly 8 trials and examined different outcomes than our
nalyses. Evaluating the superiority of interventions within
lasses requires sample sizes vastly beyond those evaluating
lacebo or inert control interventions. Until such time,
ndirect evidence using established strategies should be
pplied to provide judicious clinical and policy decision
aking (63).
There are several important strengths to our meta-
nalyses that should be considered when interpreting this
tudy. We used extensive searching of electronic databases
o identify studies. We keep a rolling database of statin trials
o ensure that we have all relevant studies. To reduce bias,
e conduct our searches independently, in duplicate. We
xtensively searched the bibliographies of published trials,
eviews, and health technology assessments to identify
npublished or obscure articles. We evaluated the individual
omponents of composite end points. We used advanced
ethodological approaches to pool and conduct sensitivity
nalyses.
There are also several limitations to consider when
ty
rvention
ibility intervals.ortali
ch inte
% crednterpreting our meta-analysis. It is possible that publication
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Primary Prevention of CVD November 25, 2008:1769–81ias contributes to our analysis; however, our searches were
horough and there was no indication of asymmetry on
unnel plots of the pooled outcomes (data not displayed).
e did not find any simvastatin trials that met our inclusion
riteria, although simvastatin is the least costly statin avail-
ble. It is possible, and indeed likely (34), that simvastatin
xerts a primary preventive effect, but no evidence is
vailable. Given the number of studies available, we chose to
onduct univariate regression to determine whether study
uality contributed to meta-analysis heterogeneity and
ound that with allocation concealment, it did. It is possible
hat if there had been more studies, we could have identified
Figure 8 Mixed-Treatment Comparison Analysis of Cardiovascu
Forest plot of mixed-treatment comparisons examining relative effectiveness of ea
cardiovascular disease mortality. Estimates are pooled odds ratios with bars repre
ixed-Treatment Comparisons offfectiveness, All- ause M rtality
Table 3 Mixed-Treatment Comparisons ofEffectiveness, All-Cause Mortality
Treatment Comparison Odds Ratio
95% Credible
Interval
Atorvastatin versus placebo 0.88 (0.77–0.99)
Fluvastatin versus placebo 1.04 (0.81–1.32)
Pravastatin versus placebo 0.92 (0.85–1.00)
Lovastatin versus placebo 0.95 (0.69–1.27)
Fluvastatin versus atorvastatin 1.18 (0.88–1.55)
Pravastatin versus atorvastatin 1.05 (0.90–1.22)
Lovastatin versus atorvastatin 1.08 (0.76–1.48)
Pravastatin versus fluvastatin 0.90 (0.68–1.16)
Lovastatin versus fluvastatin 0.92 (0.61–1.34)
Lovastatin versus pravastatin 1.03 (0.74–1.39)urther contributing covariates, but we wanted to avoid data
redging and identifying spurious relationships (29,64).
inally, we did not examine harmful effects of the individual
tatins because of the small number of included studies. A
ecent meta-analysis of harms associated with statins indi-
ated that atorvastatin was associated with greater adverse
vents than other statins (59).
Conducting meta-analyses in cardiac trials presents an
mportant methodological challenge. Many cardiovascular
rials use composite end points of their primary end points,
hereby they combine various end points, but with little
requency of the same end points among trials. For example,
isease Mortality
rvention for
g 95% credibility intervals.
ixed-Treatment Comparisons offfectiveness, Cardiovascular Disease Mortality
Table 4 Mixed-Treatment Comparisons ofEffectiveness, Cardiovascular Disease Mortality
Treatment Comparison Odds Ratio
95% Credible
Interval
Atorvastatin versus placebo 0.88 (0.69–1.11)
Fluvastatin versus placebo 0.78 (0.52–1.11)
Pravastatin versus placebo 0.90 (0.80–1.02)
Lovastatin versus placebo 0.70 (0.35–1.23)
Fluvastatin versus atorvastatin 0.89 (0.56–1.35)
Pravastatin versus atorvastatin 1.04 (0.79–1.34)
Lovastatin versus atorvastatin 0.80 (0.38–1.47)
Pravastatin versus fluvastatin 1.20 (0.79–1.75)
Lovastatin versus fluvastatin 0.93 (0.41–1.79)
Lovastatin versus pravastatin 0.77 (0.38–1.38)lar D
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November 25, 2008:1769–81 Primary Prevention of CVDtrial may report a primary composite outcome of all-cause
ortality, MI, and rehospitalization. Such an end point is
seful for identifying a primary outcome unlikely to occur in
clinical trial, thus conserving power, but is unhelpful if the
nvestigators fail to report the individual outcomes across
he composite symptoms. We have previously reviewed the
ole of composite outcomes in cardiovascular trials and
ound that composite outcomes can be misleading because
hey place similar weight on minor outcomes (such as
ehospitalization) and major outcomes (such as all-cause
ortality) (65,66). We do not believe that composite
utcomes should be pooled in a meta-analysis if the indi-
idual components of the composite are not provided. In
his study, we extracted data on individual outcomes, as
vailable.
Our study stands to inform the 3 other published meta-
nalyses examining statins in primary prevention for several
easons (7–9). All of these analyses found differing benefits
f statins for major coronary events and mortality, although
he direction of effect was consistently protective. The most
bvious explanation for this is that the previous meta-
nalyses did not include a sufficient number of studies. For
xample, for the all-cause mortality analysis, Ward et al. (8)
ncluded only 2 studies (RR: 0.83, 95% CI: 0.70 to 0.98,
 0.03), Thavendiranathan et al. (7) included only 6
tudies (RR: 0.93, 95% CI: 0.86 to 1.01) and the Canadian
gency for Drugs and Technologies in Health (9) included
studies (RR: 0.95, 95% CI: 0.87 to 1.03), although they
ad data on 14. Our study identified 20 completed trials, all
f which were available at the time those studies were
onducted and should have met their inclusion criteria.
We think that our statistical techniques are more meth-
dologically sound compared with previous analyses. For
xample, Thavendiranathan et al. (7) conducted a repeated
eta-regression of 6 covariates, when they had only 7 trials.
ome would argue whether any sensitivity analysis should be
onducted on such a small number of included trials, let
lone 6 analyses (29). Further, they included only studies
hat had a minimum of 100 events. Yet the purpose of a
eta-analysis is to increase the number of events across
rials by pooling them, so excluding studies based on event
ates is misleading. The Canadian Agency for Drugs and
echnologies in Health report, among several issues, iden-
ified only 14 trials, but chose to exclude 8 trials based on
rbitrary study quality thresholds (9). This approach is
argely considered inappropriate and excludes valuable trial
nformation (67).
We previously assessed the role of statin therapy in
rimary stroke prevention and stroke mortality and found
herapeutic effects similar to this analysis. In our stroke-
pecific article of 42 trials enrolling 121,285 at-risk patients
54), we found that statins were ineffective at preventing
troke mortality (RR: 0.99, 95% CI: 0.80 to 1.21) but were
ffective at preventing all strokes (RR: 0.84, 95% CI: 0.78 to
.90). This therapeutic preventive effect was largely driven
y the prevention of nonhemorrhagic cerebrovascular events aRR: 0.81, 95% CI: 0.69 to 0.84) rather than hemorrhagic
trokes (RR: 0.94, 95% CI: 0.68 to 1.30). Together with
his analysis of major clinical outcomes, the inferences
egarding the role of statins in primary prevention are
verwhelmingly convincing.
In this analysis, we included 3 trials that enrolled mostly
43) or only (40,42) patients with diabetes. However, per
ur inclusion criteria, the majority of these patients were not
igh risk. Earlier population-based work suggests that there
s a range of cardiovascular risk among diabetic patients,
ith younger diabetic patients not having the same high risk
s older diabetic patients (68). We, too, believe that there is
continuum of risk among diabetic patients, and we do not
elieve that younger, lower-risk patients should be consid-
red at the same risk as those patients enrolled in secondary
revention studies. A recent meta-analysis showed that
tatins confer risk reduction to both high- and low-risk
iabetic patients (17). In fact, in that analysis, the magni-
ude of benefit of statins was similar between diabetic
atients without prior history of vascular disease, diabetic
atients with a history of vascular disease, and nondiabetic
atients. We feel justified in including young and low-risk
iabetic patients in a primary prevention analysis. We
xcluded trials in high-risk diabetic patients because we
ccept that their expected event rates are similar to patients
ith established vascular disease.
As with our previous meta-analysis on primary preven-
ion of stroke (54), our analysis did not show an association
etween a reduction in LDL cholesterol and mortality or
orbidity. The lack of statistical significance in the trend of
educed morbidity and mortality with a reduction in LDL
ay be a reflection of the restricted variance in the meta-
egression technique, or it may genuinely indicate that the
ajor benefit of statins is not in LDL reduction. Statins
ave a variety of pleiotropic properties that are thought to
onvey cardiovascular protection unrelated to changes in
holesterol profile. They have been shown to modulate
nflammatory reactions, improve endothelial function, sta-
ilize plaques, and prevent thrombus formation (69).
We hope that this newest contribution can put to rest the
ebate on statin effectiveness for primary prevention and
hat the debate should now move to better understand the
linical and pharmacoeconomic criteria to delineate when to
nitiate statins rather than whether to. Treating all patients
t risk of cardiovascular events would mean treating a very
arge number of people and could have important implica-
ions for public health costs, insurability, and health re-
ource utilization. Low-risk patients are likely to receive
ittle risk reduction from statin therapy, whereas moderate-
nd high-risk patients are likely to receive substantial
enefit. The benefits, risks, and costs of lifelong therapies
hould be balanced and carefully weighed against other
reventative agents such as aspirin. As policy makers aim to
evelop guidelines on widespread use of statins, the relative
ffectiveness of statins is important to determine whether
nd what statins health ministries should be supplying.
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ead trials, to determine whether individual statins provide
iffering protection from clinically important events. Until
uch time, clinicians are justified in discussing differing
tatin therapy with high-risk patients.
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